Yazarlar |
Mustafa Kemal Celen
Dicle University, Faculty of Medicine, Turkey |
Kamuran Turker
Bağcilar Eğitim ve Araştirma Hastanesi, Turkey |
Nefise Oztoprak
Antalya Education and Research Hospital, Turkey |
Alper Sener
Çanakkale Onsekiz Mart Üniversitesi, Turkey |
Nazan Tuna
Sakarya Üniversitesi, Turkey |
Nevin Ince
Nevsehir State Hospital, Turkey |
Ilknur Erdem
Tekirdağ Namık Kemal Üniversitesi, Turkey |
Nese Saltoglu
Istanbul University-Cerrahpasa, Turkey |
Davut Ozdemir
Düzce Üniversitesi, Turkey |
Tuba Dal
Dicle University, Faculty of Medicine, Turkey |
Mustafa Kasım KARAHOCAGİL
Kırşehir Ahi Evran Üniversitesi, Türkiye |
Fatma Sirmatel
Bolu Abant İzzet Baysal Üniversitesi, Turkey |
Fusun Zeynep Akcam
Isparta University of Applied Sciences, Turkey |
Fatma Eksi Polat
Bağcilar Eğitim ve Araştirma Hastanesi, Turkey |
Mehmet Cabalak
T. C. Sağlık Bakanlığı, Bingol Devlet Hastanesi, Turkey |
Suzan Sacar
Çanakkale Onsekiz Mart Üniversitesi, Turkey |
Selma Tosun
Manisa State Hospital, Turkey |
Fehmi Tabak
Istanbul University-Cerrahpasa, Turkey |
Özet |
Chronic hepatitis B is a major public health problem in our country. Hepatitis A vaccination in HBV carriers who did not encounter with Hepatitis A virus is also significant. We aimed to evaluate the rate of exposure to HAV in HBsAg-positive persons, and the distribution of seronegative individuals according to age groups. Medical records of 4793 patients from 14 centers who were positive for hepatitis B surface antigen (HBsAg). A total 3514 cases (73.3%) were male and 1279 (26.7) were female. The HBsAg positive patients who were previously tested for HAV IgG at the time of firstly admitted to a center. HBsAg positive patients who were previously not tested for HAV IgG were tested and these . patients were confirmed serologically for HAV. The distribution of cases according to age were determined. In this study, 4793 HBsAg-positive patients were evaluated. The ratio of testing of anti-HAV IgG was very low during the first visit (54.2%). Seronegativity was highest in the age group under 19 years of age (26.2%) followed by 20-25 age group (15.5%) and 26-29 age group (12.5%). Testing of HAV serology should not be ignored in especially HBsAg-positive young adults and seronegative young adults should be vaccinated. |
Anahtar Kelimeler |
Anti-HAV IgG | HBsAg | Hepatitis A |
Makale Türü | Özgün Makale |
Makale Alt Türü | SCOPUS dergilerinde yayımlanan tam makale |
Dergi Adı | Journal of Pure and Applied Microbiology |
Dergi ISSN | 0973-7510 |
Makale Dili | İngilizce |
Basım Tarihi | 08-2014 |
Cilt No | 8 |
Sayı | 4 |
Sayfalar | 3063 / 3068 |